OXT and neoplasm: To determine whether the SEAKER platform could improve anti-tumor efficacy and decrease toxicity, B16-SIIN tumor-bearing mice in our syngeneic model were engrafted with β-Lac OT-1 SEAKER cells on day 0, then treated with Ceph-AMS on days 4–8 (4 mg/kg, BID for 10 doses) (Figure 5A).